Looking Into Ambrx Biopharma’s Recent Short Interest
Ambrx Biopharma’s (NYSE:AMAM) short percent of float has fallen 67.62% since its last report. The company recently reported…
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic UC.
Johnson & Johnson’s Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and Kenvue split-off.
Assessing Ambrx Biopharma: Insights From 7 Financial Analysts
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Ambrx Biopharma…
Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday.
The Dow traded up 0.35% to 37,596.43 while the NASDAQ rose 1.89% to 14,799.21. The S&P 500 also rose, gaining, 1.11% to 4,749.41.
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.
Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Harpoon Therapeutics (NASDAQ:HARP) stock moved upwards by 112.4% to $22.41 during Monday’s regular session. The market value…
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 1% on Monday.
The Dow traded down 0.19% to 37,396.28 while the NASDAQ rose 1.20% to 14,698.88. The S&P 500 also rose, gaining, 0.55% to 4,722.93.
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma
Johnson & Johnson (NYSE:JNJ) has announced a merger with Ambrx Biopharma (NASDAQ:AMAM) that is expected to be completed…